Clinical Trial ResultsCGON upgraded to Buy from Neutral after positive clinical data presented at AUA, highlighting cretostimogene's high potential in treating high-risk non-muscle invasive bladder cancer and setting the stage for significant market penetration.
Market OpportunityAnalysts identify a large commercial opportunity for cretostimogene in the non-muscle invasive bladder cancer market, estimated at $2.5B, indicating a substantial growth prospect for CGON's leading treatment.
Safety And EfficacyPhysicians express a preference for cretostimogene based on its safety profile, durability of efficacy, and unique mechanism of action, suggesting a competitive edge over other development-stage drugs.